Pharmaceutical - Respiratory and Pulmonary, Neurological

Filter

Popular Filters

Pharmacovigilance Risk Assessment Committee April meeting highlights

Pharmacovigilance Risk Assessment Committee April meeting highlights

11-04-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation…

Cardio-vascularEuropeMen's HealthNeurologicalPharmaceuticalRegulationRespiratory and Pulmonary

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay

11-10-2013

The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

Bayer's PAH drug candidate riociguat gets US priority review; Sativex rescheduled in UK

08-04-2013

The US Food and Drug Administration has granted priority review to German drug major Bayer's (BAYN: DE)…

BayerEuropeGW PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryriociguatSativex

Europe's CHMP issues positive opinions on aclidinium, Fycompa, Inlyta and NovoThirteen

27-05-2012

At its regular monthly meeting last week, the European Medicines Agency's Committee for Medicinal Products…

AlmirallBretaris GenuairEisaiEklira GenuairEuropeFycompaInlytaNeurologicalNovo NordiskNovoThirteenOncologyPfizerPharmaceuticalRespiratory and Pulmonary

AstraZeneca in deal with Galapagos; view on Seroquel law suit

15-03-2012

BioFocus and Argenta, service companies of Netherlands-based Galapagos (Euronext: GLPG), yesterday announced…

Argenta DiscoveryAstraZenecaBioFocusGalapagosLegalNeurologicalPharmaceuticalResearchRespiratory and PulmonarySeroquelSeroquel XR

FDA panels back Forest and Almirall COPD drug and Chelsea’s Northera for NOH

24-02-2012

The US Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 12…

aclidiniumAlmirallBiotechnologyChelsea TherapeuticsEkliraForest LaboratoriesNeurologicalNorth AmericaNortheraPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Newron updates on deal Meiji Seika Pharma deal; Almirall out-licenses in Korea

14-02-2012

Italy’s Newron Pharmaceuticals (SIX: NWRN) yesterday said it has finalized a definitive license…

aclidiniumAlmirallAsia-PacificDaewoongLicensingMeiji Seika PharmaNeurologicalNewron PharmaPharmaceuticalRespiratory and Pulmonarysafinamide

Johnson & Johnson stops Doribax trial; reportedly agrees Risperdal settlement

09-01-2012

The US Food and Drug Administration says that a recent clinical trial with Doribax (doripenem) being…

DoribaxFinancialJanssenJohnson & JohnsonLegalNeurologicalNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRisperdal

Anti-inflammatory therapeutics market to grow to $85.9 billion in 2017

06-11-2011

The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications.…

Anti-Arthritics/RheumaticsGastro-intestinalsMarkets & MarketingNeurologicalPharmaceuticalRespiratory and Pulmonary

Back to top